Lotte Biologics to Participate in World ADC Following CPHI Worldwide 2025

Strengthening Global Competitiveness in the ADC CDMO Market

Lotte Biologics announced on November 3 that it has successfully completed its participation in 'CPHI Worldwide,' the world's largest pharmaceutical and biotechnology exhibition, and will also take part in 'World ADC San Diego 2025' (World ADC), which will be held in San Diego, United States.

Booth view of Lotte Biologics at 'CPHI Worldwide' held in Frankfurt, Germany from the 28th to the 30th of last month (local time). Lotte Biologics

Lotte Biologics participated in 'CPHI Worldwide,' held in Frankfurt, Germany from October 28 to 30 (local time). The company explained that it expanded its global potential customer base through proactive activities, including holding more than 40 new partnership meetings during the event. In particular, Lotte Biologics signed a strategic letter of intent (LOI) for business cooperation with SK Pharmteco to target the antibody-drug conjugate (ADC) market at the event.

Following this, Lotte Biologics plans to participate in World ADC, which will be held in San Diego, United States from December 3 to 6 (local time). Marking its 16th edition this year, World ADC is the largest event in the field of antibody-drug conjugates. This year, more than 1,400 global experts and entrepreneurs are expected to gather to share the latest technological trends and research achievements.

On the first day of the event, Jang Gunhee, Head of Technology Development at Lotte Biologics, will give a presentation on "Accelerating Antibody-Drug Conjugate Development and Manufacturing through the ADC Platform." The presentation will highlight Lotte Biologics' competitive edge in ADC CDMO services, including its state-of-the-art production infrastructure covering everything from ADC development to GMP manufacturing, its proprietary hydrophilic linker technology called Soluplex, and its flexible and efficient systems that support rapid transition to clinical and commercial production.

James Park, CEO of Lotte Biologics, stated, "By leveraging our global production infrastructure based on dual sites in the United States and Korea and our end-to-end services, we will reduce our clients' development risks and accelerate commercialization. Building on the global interest and cooperative momentum confirmed at CPHI, we will further strengthen our position as a global ADC CDMO at World ADC."

This content was produced with the assistance of AI translation services.